Centessa Pharmaceuticals plc
CNTA
$12.30
$0.4653.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -235.76M | -161.27M | -157.35M | -138.42M | -151.09M |
| Total Depreciation and Amortization | 342.00K | 354.00K | 358.00K | 359.00K | 310.00K |
| Total Amortization of Deferred Charges | 600.00K | 604.00K | 602.00K | 602.00K | 500.00K |
| Total Other Non-Cash Items | 70.60M | 36.45M | 32.92M | 9.46M | 8.76M |
| Change in Net Operating Assets | 22.16M | -6.45M | -22.84M | -21.80M | -18.83M |
| Cash from Operations | -142.06M | -130.31M | -146.31M | -149.79M | -160.34M |
| Capital Expenditure | -34.00K | -62.00K | -71.00K | -81.00K | -169.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 31.30M | -11.95M | -8.20M | -23.83M | -126.84M |
| Cash from Investing | 31.27M | -12.01M | -8.27M | -23.91M | -127.00M |
| Total Debt Issued | 109.34M | -- | -- | -- | -- |
| Total Debt Repaid | -110.10M | -- | -- | -- | -- |
| Issuance of Common Stock | 370.83M | 371.88M | 139.67M | 31.61M | 21.12M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.32M | -3.73M | -2.76M | -- | -- |
| Cash from Financing | 364.75M | 368.15M | 136.91M | 31.61M | 21.12M |
| Foreign Exchange rate Adjustments | 1.23M | -2.31M | -185.00K | 316.00K | 615.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 255.19M | 223.53M | -17.85M | -141.77M | -265.61M |